The current study aimed to investigate the effects of TUG1 on the migration and invasion of hepatoma cells.
Materials and Methods:
The expressions of TUG1, miR-137, and AKT2 were detected in hepatoma tissues and cells by performing quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The correlations among TUG1, miR-137, and AKT2 were predicted by bioinformatics analysis and confirmed by dual-luciferase reporter assay, and Pearson test was performed to analyze their relevance. The effects of TUG1, miR-137, and AKT2 on viability, migration, and invasion of transfected hepatoma cells were detected by CCK-8, wound scratch, and Transwell. Epithelial–mesenchymal transition (EMT)-related protein levels were determined by Western blot and qRT-PCR.
Results:
TUG1 was highly expressed in hepatoma tissues and cells. Silencing TUG1 expression inhibited the viability, migration, and invasion of hepatoma cells. TUG1 targeted miR-137 and the two was negatively correlated, and silencing TUG1 expression inhibited the effects of low-expressed miR-137 on promoting proliferation, migration, and invasion of hepatoma cells. AKT2 was predicted to be the target gene for miR-137, and the two were negatively correlated. Moreover, inhibiting miR-137 expression promoted the expression of MMP2, MMP9, and N-cadherin and inhibited E-cadherin expression, while silencing TUG1 expression reversed the effects of low-expressed miR-137 on EMT-related protein levels.
Conclusion:
LncRNA TUG1 promotes hepatocellular carcinoma migration and invasion through targeting the miR-137/AKT2 axis.
Get full access to this article
View all access options for this article.
References
1.
WuDH, JiaCC, ChenJ, et al.Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. Tumour Biol, 2014; 35:12225–12233.
2.
OrcuttST, AnayaDA. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control, 2018; 25:1073274817744621.
3.
FuJ, WangH. Precision diagnosis and treatment of liver cancer in China. Cancer Lett, 2018; 412:283–288.
4.
HabitoCM. Editorial: Radioembolization in the treatment of liver cancer: A multidisciplinary approach for individualized therapy. Front Oncol, 2015; 5:216.
5.
TakekumaM, KasamatsuY, KadoN, et al.The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review. J Obstet Gynaecol Res, 2017; 43:617–626.
BhanA, SoleimaniM, MandalSS. Long noncoding RNA and cancer: A new paradigm. Cancer Res, 2017; 77:3965–3981.
8.
LiJ, LiZ, ZhengW, et al.LncRNA-ATB: An indispensable cancer-related long noncoding RNA. Cell Prolif, 2017; 50:e12381.
9.
XuY, GeZ, ZhangE, et al.The lncRNA TUG1 modulates proliferation in trophoblast cells via epigenetic suppression of RND3. Cell Death Dis, 2017; 8:e3104.
10.
KatsushimaK, NatsumeA, OhkaF, et al.Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun, 2016; 7:13616.
11.
LinYH, WuMH, HuangYH, et al.Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma. Hepatology, 2018; 67:188–203.
12.
LeeE, WangJ, YumotoK, et al.DNMT1 regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia, 2016; 18:553–566.
13.
MatosML, LapyckyjL, RossoM, et al.Identification of a novel human E-Cadherin splice variant and assessment of its effects upon EMT-related events. J Cell Physiol, 2017; 232:1368–1386.
14.
WangM, RenD, GuoW, et al.Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol, 2014; 45:362–372.
15.
PaulaTG, ZanellaBTT, FantinattiBEA, et al.Food restriction increase the expression of mTORC1 complex genes in the skeletal muscle of juvenile pacu (Piaractus mesopotamicus). PLoS One, 2017; 12:e0177679.
16.
SakabeT, AzumiJ, UmekitaY, et al.Prognostic relevance of miR-137 in patients with hepatocellular carcinoma. Liver Int, 2017; 37:271–279.
17.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001; 25:402–408.
18.
WangF, YingHQ, HeBS, et al.Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget, 2015; 6:7899–7917.
19.
LiSP, XuHX, YuY, et al.LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget, 2016; 7:42431–42446.
20.
ZhouT, GaoY. Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma. World J Surg Oncol, 2016; 14:8.
21.
ZhaoL, SunH, KongH, et al.The Lncrna-TUG1/EZH2 axis promotes pancreatic cancer cell proliferation, Migration and EMT phenotype formation through sponging Mir-382. Cell Physiol Biochem, 2017; 42:2145–2158.
22.
NiuY, MaF, HuangW, et al.Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer, 2017; 16:5.
23.
CaoJ, HanX, QiX, et al.TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p. Int J Oncol, 2017; 51:1115–1123.
24.
HuangMD, ChenWM, QiFZ, et al.Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. Mol Cancer, 2015; 14:165.
25.
LvJ, KongY, GaoZ, et al.LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma. Int J Biochem Cell Biol, 2018; 101:19–28.
26.
HanY, LiuY, GuiY, et al.Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol, 2013; 107:555–559.
27.
SunJ, DingC, YangZ, et al.The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition. J Transl Med, 2016; 14:42.
28.
LiuLL, LuSX, LiM, et al.FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget, 2014; 5:5113–5124.
29.
WuDC, ZhangMF, SuSG, et al.HEY2, a target of miR-137, indicates poor outcomes and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget, 2016; 7:38052–38063.
30.
DeyN, DeP, Leyland-JonesB. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. Pharmacol Ther, 2017; 175:91–106.
31.
TanY, HuangN, ZhangX, et al.KIAA0247 suppresses the proliferation, angiogenesis and promote apoptosis of human glioma through inactivation of the AKT and Stat3 signaling pathway. Oncotarget, 2016; 7:87100–87113.
32.
DiY, ZhangY, NieQ, et al.CCN1/Cyr61-PI3K/AKT signaling promotes retinal neovascularization in oxygen-induced retinopathy. Int J Mol Med, 2015; 36:1507–1518.
33.
PoppR, LiH, LeBlancA, et al.Immuno-matrix-assisted laser desorption/ionization assays for quantifying AKT1 and AKT2 in breast and colorectal cancer cell lines and tumors. Anal Chem, 2017; 89:10592–10600.
34.
ZhangJ, LiG, ChenY, et al.Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer, 2017; 8:1849–1864.
35.
AttoubS, ArafatK, Kamel HammadiN, et al.Akt2 knock-down reveals its contribution to human lung cancer cell proliferation, growth, motility, invasion and endothelial cell tube formation. Sci Rep, 2015; 5:12759.
36.
WangL, YaoJ, SunH, et al.miR-302b suppresses cell invasion and metastasis by directly targeting AKT2 in human hepatocellular carcinoma cells. Tumour Biol, 2016; 37:847–855.
37.
LuZ, WangM, WuS, et al.MicroRNA-137-regulated AKT serine/threonine kinase 2 inhibits tumor growth and sensitizes cisplatin in patients with non-small cell lung cancer. Oncol Lett, 2018; 16:1876–1884.
38.
LuC, HeY, DuanJ, et al.Expression of Wnt3a in hepatocellular carcinoma and its effects on cell cycle and metastasis. Int J Oncol, 2017; 51:1135–1145.
39.
MaoXY, LiQQ, GaoYF, et al.Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis. Cancer Lett, 2016; 381:133–137.
40.
WangH, WangC, TianW, YaoY. The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. Oncotarget, 2017; 8:72157–72166.
41.
Rodriguez-MonterrosasC, Diaz-AragonR, Leal-OrtaE, et al.Insulin induces an EMT-like process in mammary epithelial cells MCF10A. J Cell Biochem, 2018; 119:4061–4071.
42.
HeR, ZhangFH, ShenN. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother, 2017; 95:331–338.
